Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 1

3(37.5%)

Phase 2

1(12.5%)

8Total

Phase 3(4)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04152083Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

Role: collaborator

NCT04197349Phase 1Completed

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

Role: collaborator

NCT02974153Phase 3Completed

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Role: lead

NCT02559895Phase 3Completed

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Role: lead

NCT02985398Phase 3Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Role: lead

NCT02275117Phase 2Completed

A Multicenter Assessment of ALD403 in Chronic Migraine

Role: lead

NCT01772524Phase 1Completed

Safety, Efficacy and Pharmacokinetics of ALD403

Role: lead

NCT01579383Phase 1Completed

Safety Tolerability and Pharmacokinetics of ALD403

Role: lead

All 8 trials loaded